Key facts
- Reselute’s last known valuation is $13.0M (Nov 2025).
- It has raised $5.1M across 3 recorded rounds; the latest was Seed Round ($2.4M) in May 2025.
- Notable investors include US National Science Foundation, Duke Capital Partners, Charlotte Angel Fund, Western Skies Partners.
- Reselute has filed 4 Form Ds with the SEC since 2023, most recently Jun 2025 ($1.4M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Reselute
Funding rounds
3 roundsAbout Reselute
Operator of a medical technology company intended for treating orthopedic implant-related infections. The company designs, develops, and validates the proof of concept for an orthopedic spacer using technologies, enabling doctors to accelerate treatment and improve patient care.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2021
- Employees
- 7
- Website
- reselutemedical.com/
- Ownership
- Privately Held (backing)
Reselute doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reselute shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reselute in its N-PORT filings yet. We sweep new filings monthly.